Prediction of short term re-exacerbation in patients with acute exacerbation of chronic obstructive pulmonary disease

International Journal of COPD

Volumn 10, Issue , 2015, Pages 1265-1273

  Liu, Dong ^a   Peng, Shao Hua ^a,b   Zhang, Jing ^a   Bai, Si Hong ^a,c   Liu, Hai Xia ^a   Qu, Jie Ming ^a,d  

^a FUDAN UNIVERSITY   (China)

^b Shaowu Municipal Hospital   (China)

^c The People s Hospital of Song County   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acute exacerbation; Chronic obstructive pulmonary disease; Re exacerbation; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; OXYGEN;

AGED; ARTICLE; BODY MASS; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NONINVASIVE VENTILATION; OBSERVATIONAL STUDY; OXYGEN THERAPY; PLEURA EFFUSION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; AREA UNDER THE CURVE; DECISION SUPPORT SYSTEM; DISEASE COURSE; HEALTH STATUS; HEALTH STATUS INDICATOR; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

AGED; AREA UNDER CURVE; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HEALTH STATUS INDICATORS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84936861860     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S83378     Document Type: Article

References (30)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
2. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005-1012.
3. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009; 103(5):692-699.
4. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009; 374(9691):704-711.
5. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009;180(12): 1189-1195.
6. Almagro P, Soriano JB, Cabrera FJ, et al; Working Group on COPD, Spanish Society of Internal Medicine. Short-and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014;145(5):972-980.
7. Roche N, Zureik M, Soussan D, Neukirch F, Perrotin D; Urgence BPCO (COPD Emergency) Scientific Committee. Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. Eur Respir J. 2008;32(4):953-961.
8. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 suppl 2):398s-401s.
9. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29(6):1224-1238.
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD; 2015. Available from: http://www.goldcopd.org/. Accessed January 1, 2015.
11. Mahler DA, Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1992;145(2 pt 1):467-470.
12. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-654.
13. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144(5):1202-1218.
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognositic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
15. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1): 29-36.
16. Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax. 2012;67(3):238-243.
17. Leivseth L, Brumpton BM, Nilsen TI, Mai XM, Johnsen R, Langhammer A. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013;68(10):914-921.
18. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301-305.
19. Connolly MJ, Lowe D, Anstey K, et al; British Thoracic Society and the Royal College of Physicians Clinical Effectiveness Evaluation Unit (CEEu). Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation. Thorax. 2006;61(10):843-848.
20. Chang CL, Sullivan GD, Karalus NC, Mills GD, McLachlan JD, Hancox RJ. Predicting early mortality in acute exacerbation of chronic obstructive pulmonary disease using the CURB65 score. Respirology. 2011;16(1):146-151.
21. Stone RA, Lowe D, Potter JM, Buckingham RJ, Roberts CM, Pursey NJ. Managing patients with COPD exacerbation: does age matter? Age Ageing. 2012;41(4):461-468.
22. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how? BMJ. 2009;338:b375.
23. Gudmundsson G, Gislason T, Lindberg E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res. 2006;7:109.
24. Cazzola M, Di Perna F, D’Amato M, Califano C, Matera MG, D’Amato G. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med. 2001;95(11):917-921.
25. Cazzola M, Matera MG. Long-acting beta(2) agonists as potential option in the treatment of acute exacerbations of COPD. Pulm Pharmacol Ther. 2003;16(4):197-201.
26. Segreti A, Fiori E, Calzetta L, et al. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013;26(6):630-634.
27. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165(5):698-703.
28. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29(4):660-667.
29. Ställberg B, Selroos O, Vogelmeier C, Andersson E, Ekström T, Larsson K. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res. 2009;10:11.
30. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.